ZEALAND PHARMA AS

Augustine Therapeutics has appointed Rie Schultz Hansen, PhD, as Chief Scientific Officer to lead the advancement of lead candidate AGT-100216 through Phase I/II clinical trials for Charcot-Marie-Tooth disease.

DelveInsight's 2025 pipeline report reveals a robust obesity therapeutics landscape with over 80 companies developing more than 100 pipeline drugs across various clinical stages.

Zealand Pharma CEO Adam Steensberg has indicated that the company's obesity drug candidate petrelintide could reach the market earlier than planned following a strategic partnership with Roche.

Zealand Pharma has appointed Utpal Singh as Chief Scientific Officer to lead discovery research and translational sciences, bringing nearly 25 years of pharmaceutical industry experience to the company.

• Ironwood Pharmaceuticals has announced that a confirmatory Phase 3 trial will be required for apraglutide in short bowel syndrome with intestinal failure, following its $1 billion acquisition of VectivBio. • The GLP-2 analogue apraglutide was positioned as a potential blockbuster drug with projected annual sales of $1 billion, offering advantages over existing treatments like Takeda's Gattex through improved potency and weekly dosing. • Ironwood has engaged Goldman Sachs to explore strategic alternatives for the company while continuing the long-term extension study and working with the FDA on the design of the confirmatory trial.

Roche has entered into a $5.3 billion collaboration with Zealand Pharma to co-develop petrelintide, a promising amylin analog for obesity treatment, both as monotherapy and in combination with Roche's incretin asset CT-388.

Boehringer Ingelheim and Zealand Pharma have initiated three phase 3 trials for survodutide, a glucagon/GLP-1 receptor dual agonist that achieved up to 19% weight loss in phase 2 studies.

The FDA approved mirikizumab (Omvoh) for Crohn's disease, marking its second approval in IBD after ulcerative colitis, based on positive Phase 3 trial results.

The FDA issued a Complete Response Letter for Zealand Pharma's glepaglutide, a GLP-2 analog, intended for short bowel syndrome (SBS) treatment, citing insufficient evidence of efficacy and safety.

Zealand Pharma's survodutide, a unique anti-obesity molecule, is currently in Phase 3 trials, potentially offering a more effective or tolerable alternative for weight loss.